scientist in lab

Pipeline Overview

Armata’s therapeutic phage candidates aim to address areas of significant unmet clinical need, by targeting key antibiotic-resistant bacteria including those on the World Health Organization’s global priority pathogens list. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. Proprietary synthetic phage candidates designed to target an undisclosed infectious disease agent are being developed in partnership with Merck. Armata is committed to advancing phage with drug development expertise that spans bench to clinic including in-house phage-specific cGMP manufacturing.

divider with Armata logo
Program Discovery Preclinical IND-Enabling Phase 1b/2 Partner
Pseudomonas aeruginosa
Respiratory Infections
AP-PA02
CF
Swarm logo
cff logo
AP-PA02
NCFB
tailwind logo
 
AP-PA03
Pneumonia
Staphylococcus aureus
AP-SA02
Bacteremia
disarm logo
US DoD*
Bacteremia
PJI
 
Phage Candidate Program Phase Partner
AP-PA02
CFswarm logo Phase 1b/2 cff logo
NCFBtailwind logo Phase 2
AP-PA03
Pneumonia IND-Enabling  
AP-SA02
Bacteremiadisarm logo Phase 1b/2 US DoD*
PJI IND Cleared

CF: cystic fibrosis; NCFB: non-CF bronchiectasis; PJI: prosthetic joint infection
SWARM-P.a. NCT Number; NCT04596319; Cystic Fibrosis Foundation TrialFinder
diSArm NCT Number: NCT05184764
*Department of Defense (Naval Medical Research Center, US Army Medical Research Acquisition Activity, Defense Health Agency)

Discovery-Stage
Partner
Engineered Phage
undisclosed target/indication
Merck
Escherichia coli
Klebsiella pneumoniae
Discovery-Stage
Partner
Engineered Phage
undisclosed target/indication
Merck
Escherichia coli
Klebsiella pneumoniae